With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...
Employees are reassessing, leaders are celebrating data that should make them nervous and job seekers are absorbing a ...
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million ...
In a complete response letter published by the FDA on Monday, the agency said a resubmission for REGENXBIO’s Hunter syndrome ...
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their ...
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche ...
This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing ...
OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered ...
FDA decisions lack majority consensus, experts agree, possibly leading to less nuanced verdicts on new drug applications.
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with CNBC, the agency confirmed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results